Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Tuesday, down -4.74% from the previous trading day, before settling in for the closing price of $0.97. Over the past 52 weeks, FATE has traded in a range of $0.87-$7.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 46.37%. While this was happening, its average annual earnings per share was recorded 4.69%. With a float of $98.49 million, this company’s outstanding shares have now reached $113.93 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is -189.23%, operating margin of -1542.63%, and the pretax margin is -1366.46%.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 14.06%, while institutional ownership is 80.81%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.44% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 7.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Looking closely at Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days average volume was 1.61 million, which is a drop from its year-to-date volume of 2.46 million. As of the previous 9 days, the stock’s Stochastic %D was 38.30%. Additionally, its Average True Range was 0.12.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 1.92%, which indicates a significant decrease from 15.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.61% in the past 14 days, which was lower than the 107.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2752, while its 200-day Moving Average is $2.7605. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $0.9489. Second resistance stands at $0.9774. The third major resistance level sits at $0.9993. If the price goes on to break the first support level at $0.8985, it is likely to go to the next support level at $0.8766. Now, if the price goes above the second support level, the third support stands at $0.8481.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 105.49 million has total of 114,597K Shares Outstanding. Its annual sales at the moment are 13,630 K in contrast with the sum of -186,260 K annual income. Company’s last quarter sales were recorded 1,860 K and last quarter income was -52,150 K.
